{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:14:48Z","timestamp":1790205288851,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T00:00:00Z","timestamp":1531094400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s13365-018-0657-x","type":"journal-article","created":{"date-parts":[[2018,7,9]],"date-time":"2018-07-09T11:20:34Z","timestamp":1531135234000},"page":"652-655","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Successful treatment of progressive multifocal leukoencephalopathy with recombinant interleukin-7 and maraviroc in a patient with idiopathic CD4 lymphocytopenia"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3527-0938","authenticated-orcid":false,"given":"Asaff","family":"Harel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Horng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarah","family":"Gustafson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Ramineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca Straus","family":"Farber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Fabian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,9]]},"reference":[{"key":"657_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nm1741","volume":"14","author":"SK Ahuja","year":"2008","unstructured":"Ahuja SK, Kulkarni H, Catano G, Agan BK, Camargo JF, He W, O'Connell RJ, Marconi VC, Delmar J, Eron J, Clark RA, Frost S, Martin J, Ahuja SS, Deeks SG, Little S, Richman D, Hecht FM, Dolan MJ (2008) CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1 infected individuals. Nat Med 14:413\u2013420","journal-title":"Nat Med"},{"issue":"8","key":"657_CR2","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/jamaneurol.2014.825","volume":"71","author":"KB Alstadhaug","year":"2014","unstructured":"Alstadhaug KB, Croughs T, Henriksen S, Leboeuf C, Sereti I, Hirsch HH, Rinaldo CH (2014) Treatment of progressive multifocal leukoencephalopathy with interleukin 7. JAMA Neurology 71(8):1030\u20131035","journal-title":"JAMA Neurology"},{"issue":"4","key":"657_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s11940-000-0053-7","volume":"2","author":"JR Berger","year":"2000","unstructured":"Berger JR (2000) Progressive multifocal leukoencephalopathy. Curr Treat Options Neurol 2(4):361\u2013368","journal-title":"Curr Treat Options Neurol"},{"issue":"1","key":"657_CR4","first-page":"59","volume":"4","author":"JR Berger","year":"1998","unstructured":"Berger JR, Pall L, Lanska D, Whiteman M (1998) Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neuro-Oncol 4(1):59\u201368","journal-title":"J Neuro-Oncol"},{"key":"657_CR5","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.4049\/jimmunol.182.1.171","volume":"182","author":"JF Camargo","year":"2009","unstructured":"Camargo JF, Quinones MP, Mummidi S et al (2009) CCR5 expression levels influence NFAT translocation, IL-2 production, and subsequent signaling events during T lymphocyte activation. J Immunol 182:1550\u20136606","journal-title":"J Immunol"},{"key":"657_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jns.2013.02.002","volume":"327","author":"M Delgado-Alvarado","year":"2013","unstructured":"Delgado-Alvarado M, Sedano MJ, Gonzalez-Quintanilla V, de Lucas EM, Polo JM, Berciano J (2013) Progressive multifocal leukoencephalopathy and idiopathic CD4 lymphocytopenia. J Neurol Sci 327:75\u201379","journal-title":"J Neurol Sci"},{"issue":"2","key":"657_CR7","doi-asserted-by":"publisher","first-page":"ofu074","DOI":"10.1093\/ofid\/ofu074","volume":"1","author":"J. Gasnault","year":"2014","unstructured":"Gasnault J, De Goer de Herve MG, Michot JM et al (2014) Efficacy of recombinant human interleukin 7 in a patient with severe lymphopenia-related progressive multifocal leukoencephalopathy. Open Forum Infect Dis 1(2):ofu074","journal-title":"Open Forum Infectious Diseases"},{"issue":"14","key":"657_CR8","doi-asserted-by":"publisher","first-page":"7256","DOI":"10.1128\/JVI.02506-10","volume":"85","author":"S Gheuens","year":"2011","unstructured":"Gheuens S, Bord E, Kesari S, Simpson DM, Gandhi RT, Clifford DB, Berger JR, Ngo L, Koralnik IJ (2011) Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndrome. J Virol 85(14):7256\u20137263","journal-title":"J Virol"},{"issue":"5","key":"657_CR9","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nri2970","volume":"11","author":"CL Mackall","year":"2011","unstructured":"Mackall CL, Fry TJ, Gress RE (2011) Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 11(5):330\u2013342","journal-title":"Nat Rev Immunol"},{"key":"657_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1212\/WNL.0000000000001713","volume":"85","author":"A Middel","year":"2015","unstructured":"Middel A, Arends JE, van Lelyveld SFL, Otto S, Schuurman R, Frijns CJM, Tesselaar K, Hoepelman AIM (2015) Clinical and immunologic effects of MVC in progressive multifocal leukoencephalopathy. Neurology 85:104\u2013106","journal-title":"Neurology"},{"issue":"2","key":"657_CR11","first-page":"e213","volume":"3","author":"DP Miskin","year":"2016","unstructured":"Miskin DP, Chalkias S, Dang X, Bord E, Batson S, Koralnik I (2016) Interleukin-7 treatment of PML in a patient with idiopathic lymphocytopenia. Neurology: Neuroimmunology Neuroinflammation 3(2):e213","journal-title":"Neurology: Neuroimmunology Neuroinflammation"},{"issue":"7","key":"657_CR12","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1086\/500400","volume":"42","author":"M. A. Rueger","year":"2006","unstructured":"Rueger MA, Miletic H, Dorries K, Wyen C, Eggers C, Deckert M, Faetkenheuer G, Jacobs AH Long-term remission in progressive multifocal leukoencephalopathy caused by idiopathic CD4+ T lymphocytopenia: a case report. Clin Infect Dis 2006; 1;42(7):e53\u20136","journal-title":"Clinical Infectious Diseases"},{"issue":"2","key":"657_CR13","doi-asserted-by":"publisher","first-page":"e60","DOI":"10.1016\/S2352-3018(14)70027-X","volume":"1","author":"J Sierra-Madero","year":"2014","unstructured":"Sierra-Madero J, Ellenberg S, Rassool MS et al (2014) A randomized, double-blind, placebo-controlled clinical trial of chemokine receptor 5 (CCR5) antagonist to decrease the occurrence of immune reconstitution inflammatory syndrome in HIV-infection: the CADIRIS Study. Lancet HIV 1(2):e60\u2013e67","journal-title":"Lancet HIV"},{"issue":"11","key":"657_CR14","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1093\/cid\/ciu682","volume":"59","author":"M Sosperda","year":"2014","unstructured":"Sosperda M, Schippling S, Yousef S et al (2014) Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1. Clin Infect Dis 59(11):1588\u20131592","journal-title":"Clin Infect Dis"},{"issue":"3","key":"657_CR15","doi-asserted-by":"publisher","first-page":"e59705","DOI":"10.1371\/journal.pone.0059705","volume":"8","author":"F Spadaro","year":"2013","unstructured":"Spadaro F, Cecchetti S, Purificato C, Sabbatucci M, Podo F, Ramoni C, Gessani S, Fantuzzi L (2013) Nuclear phosphoinositide-specific phospholipase C \u00df1 controls cytoplasmic CCL2 mRNA levels in HIV-1 gp120-stimulated primary human macrophages. PLoS One 8(3):e59705","journal-title":"PLoS One"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13365-018-0657-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-018-0657-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-018-0657-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T19:28:40Z","timestamp":1562614120000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13365-018-0657-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,9]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["657"],"URL":"https:\/\/doi.org\/10.1007\/s13365-018-0657-x","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"value":"1355-0284","type":"print"},{"value":"1538-2443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,9]]},"assertion":[{"value":"7 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Asaff Harel has received consulting fees from Teva Pharmaceuticals.Sam Horng reports no disclosures.Tarah Gustafson reports no disclosures.Anil Ramineni reports no disclosures.Rebecca Straus Farber reports no disclosures.Michelle Fabian has received consulting fees from Biogen pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}